Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
Furthermore, Brody says: They are very similar medications
The use of PEG for modification of drugs is FDA approved, non-immunogenic, non-antigenic, non-toxic, and increases the solubility of drugs in aqueous solutions
These figures come from preclinical and pharmacokinetic literature, not from approved human dosing and note the standard route for this molecule is oral
The double-blind placebo control in this study eliminates this as an explanation for the results
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 19(7):1987